Episode
HCA Healthcare Stock: It Beat Q2 but CUT Its Guidance — So Why We Say BUY
- Published
- Jul 24, 2026
- Duration seconds
- 877
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/hca-healthcare-stock-it-beat-q2-but-cut-its-guidance-so-why-we-say-buy/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/hca-healthcare-stock-it-beat-q2-but-cut-its-guidance-so-why-we-say-buy.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
HCA Healthcare (HCA) Q2 2026 — HCA Healthcare (HCA), the largest for-profit hospital operator in the U.S., delivered a headline-beating Q2 2026 — then CUT its full-year guidance. Q2 diluted EPS of $7.62 rose ~12% YoY (vs $6.83) on revenue of $20.23B (+8.7%) and adjusted EBITDA of $4.03B (+4.6%) — but the adjusted EBITDA margin compressed from 20.7% to 19.9%, and management LOWERED FY2026 guidance (EPS to $28.70–$30.50, net income to $6.3–$6.7B, adj EBITDA to $15.4–$16.1B), citing a worsening uninsured/payer-mix headwind now pegged at $1.0–$1.2B. A one-time ~$400M Florida Medicaid Supplemental catch-up roughly offset a ~$400M uninsured hit this quarter, flattering the print. The stock had already fallen ~32% from its $556 high to ~$377 (~13x earnings, ~9% FCF yield) and dropped ~7% on the July 14 preannouncement. Our leverage-adjusted owner-earnings DCF lands fair value near $400 — modestly above the price — and a buyback that has shrunk the share count ~20% in three years compounds per-share returns. Our call: BUY, 3/5. HCA Healthcare is the #1 for-profit hospital operator in America — a genuine fortress, running ~190 hospitals and 2,500+ sites of care across 20 states and the UK, led by CEO Sam Hazen — caught in a genuinely tricky moment. Q2 2026 looked strong on the surface: diluted EPS of $7.62 jumped ~12% YoY (vs $6.83), revenue rose 8.7% to $20.23B, and adjusted EBITDA reached $4.03B. But one layer down it sours: the adjusted EBITDA margin compressed from 20.7% to 19.9%, and management CUT full-year guidance — EPS to $28.70–$30.50, net income to $6.3–$6.7B, adj EBITDA to $15.4–$16.1B — as the uninsured/payer-mix headwind was revised WORSE, to $1.0–$1.2B for 2026. The root cause is policy: the enhanced ACA premium tax credits expired end-2025 and the new federal bu…